NCT06665646View on ClinicalTrials.gov

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 14, 2025

Primary Completion Date

July 27, 2026

Study Completion Date

May 4, 2027

Conditions
HIV Infections
Interventions
BIOLOGICAL

CD40.HIVRI.Env (VRIPRO)

To be administered subcutaneously as 1 mg admixed with Hiltonol, Poly-ICLC as a single dose.

BIOLOGICAL

Hiltonol Poly-ICLC-adjuvant

Vaccine adjuvant

Trial Locations (7)

10032

NOT_YET_RECRUITING

Columbia P&S CRS, New York

19104

RECRUITING

Penn Prevention CRS (Site ID# 30310), Philadelphia

30030

NOT_YET_RECRUITING

The Hope Clinic of the Emory Vaccine Center CRS, Decatur

37232

RECRUITING

Vanderbilt Vaccine (VV) CRS, Nashville

94102

RECRUITING

Bridge HIV CRS, San Francisco

98104

NOT_YET_RECRUITING

Seattle Vaccine and Prevention CRS, Seattle

02115-6110

RECRUITING

Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT06665646 - Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706 | Biotech Hunter | Biotech Hunter